Meagan Medical

Meagan Medical, Inc. is a clinical research and product development company headquartered in Vancouver, Washington, in the United States. It was established in March 2003 as the primary research component and sister company of RS Medical. The company's mission is to investigate optimal ways of managing and controlling pain by leveraging its key intellectual property in electrical stimulation therapy. It positions its work as an alternative to opiates and NSAIDs, aiming to reduce morbidity and overall healthcare costs. Meagan Medical's activities center on electrostimulation therapy for pain control, spinal cord stimulation, and a variety of other neurological applications. Its two publicly described technology programs are the DISCSS Dynamic Interferential Spinal Cord Stimulator System and Cutaneous Field Stimulation (CFS). The company states that it has over twenty years of experience in the design, development, and clinical use of interferential current (IFC) stimulation products. It believes that IFC's medium frequency range of 500–20,000 Hz, delivered as two intersecting currents that combine to reduce tissue reactance and produce a deeper stimulation field, could result in more effective pain relief than standard low-frequency spinal cord stimulation and other high-frequency SCS systems. Cutaneous Field Stimulation is described by the company as a novel form of electrotherapy to manage pain. According to Meagan Medical, CFS can provide 3–6 hours of pain relief following a 30-minute treatment. The action of CFS is achieved by stimulating specific types of nerve fibers, leveraging the nervous system anatomy, to essentially divert the brain's attention from the signal of chronic pain. The company envisions the therapy as a cost-effective adjunct to comprehensive pain management programs, intended to improve patient quality of life and reduce overall healthcare costs. As a research-oriented organization, Meagan Medical emphasizes collaboration and funding opportunities with other companies and national research entities. Its team is committed to pursuing research and collaborative relationships in pain control, spinal cord stimulation, and other neurological applications of electrostimulation therapy. The company is private and operates as part of the RS Medical group.

Meagan Medical, Inc. was established in March 2003 as the primary research component and sister company of RS Medical. It is headquartered in Vancouver, Washington, in the United States. From its founding, the company has focused on clinical research and product development in electrostimulation therapy for pain management. The company states that it has over twenty years of experience in the design, development, and clinical use of interferential current (IFC) stimulation products. Building on that experience, Meagan Medical has started product development on the DISCSS Dynamic Interferential Spinal Cord Stimulator System, which it describes as one of the most significant advances in spinal cord stimulation product history. The company's rationale is that IFC's medium frequency range of 500–20,000 Hz, delivered as two intersecting currents, combines to reduce tissue reactance and produce a deeper stimulation field, potentially resulting in more effective pain relief than standard low-frequency spinal cord stimulation and other high-frequency SCS systems. The company has also advanced Cutaneous Field Stimulation (CFS), described as a novel form of electrotherapy to manage pain. According to Meagan Medical, CFS can provide 3–6 hours of pain relief following a 30-minute treatment by stimulating specific types of nerve fibers and leveraging nervous system anatomy to divert the brain's attention from the signal of chronic pain. The company envisions CFS as a cost-effective adjunct to comprehensive pain management programs. Throughout its history, Meagan Medical has emphasized research and collaboration. Its stated mission is to investigate optimal ways of managing and controlling pain by leveraging its key intellectual property, and it sees opportunities for collaboration and funding with other companies and national research entities. The company frames its work as offering alternatives to opiates and NSAIDs to significantly reduce morbidity and costs. Its team is committed to pursuing research and collaborative relationships in pain control, spinal cord stimulation, and a variety of other neurological applications of electrostimulation therapy.

• Meagan Medical established in March 2003 as the primary research component and sister company of RS Medical.

• Company begins product development on the DISCSS Dynamic Interferential Spinal Cord Stimulator System.

• Company advances Cutaneous Field Stimulation (CFS) as a novel electrotherapy for pain management.

A clinical research and product development company developing electrostimulation therapies as alternatives to opiates and NSAIDs for pain management.

• DISCSS Dynamic Interferential Spinal Cord Stimulator System

  A spinal cord stimulation system under development that uses interferential current (IFC) in the medium frequency range of 500–20,000 Hz delivered as two intersecting currents to reduce tissue reactance and produce a deeper stimulation field.

• Cutaneous Field Stimulation (CFS)

  A novel form of electrotherapy to manage pain that can provide 3–6 hours of pain relief following a 30-minute treatment by stimulating specific types of nerve fibers.

1. 1Home | Meagan Medical, Incmeaganmedical.com
2. 2ABOUT | Meagan Medical, Incmeaganmedical.com
3. 3Meagan Medical (United States) - Wikidatawikidata.org